9:04 am CEL-SCI Corp reports 146 patients enrolled in its phase iii immunotherapy head and neck cancer trial; in accordance with study design ~ 84 of the enrolled patients have been dosed with Multikine – HedgeChatter

9:04 am CEL-SCI Corp reports 146 patients enrolled in its phase iii immunotherapy head and neck cancer trial; in accordance with study design ~ 84 of the enrolled patients have been dosed with Multikine

27 Feb

9:04 am CEL-SCI Corp reports 146 patients enrolled in its phase iii immunotherapy head and neck cancer trial; in accordance with study design ~ 84 of the enrolled patients have been dosed with Multikine

Bystocknews CVM, stock Comments Off

View todays social media effects on CVM

View the latest stocks trending across Twitter. Click to view dashboard

See who Cel is hiring next, click here to view

Author